Several National Retail Chains to Carry Product
QUEBEC CITY, Feb. 16, 2012 /CNW/ - Botaneco Corp. ("Botaneco" or the
"Corporation") (TSXV: BOT), and its distributor, Maliderma Inc., are
pleased to announce today the recent successful launch of Dermylex®, a
natural treatment for Psoriasis, in a number of National Canadian
Retail Chains. The product is commercialized under the Maliderma
Dermylex® trademark and can be found in Zellers nationally excluding
Quebec, Loblaw's Pharmacy select stores, Real Canadian Superstore,
Atlantic Superstore and Fortinos.
Dermylex® is a protein complex derived from dairy which naturally
improves the symptoms of mild to moderate Psoriasis, the most common
form of the disease. Approved by Health Canada in March 2009, Dermylex®
was issued a Natural Product Number (NPN) due to its solid safety and
efficacy profile. Dermylex® was shown in 3 clinical studies to improve
the symptoms of patients suffering from Psoriasis.
Psoriasis is a $3.4 billion market expected to double to $6.8 billion by
2019. There are multiple drugs, many with unwanted side effects, used
to treat this skin disorder. Although doctors choose treatments based
on the type and severity of the disease, the traditional approach is to
start with the mildest treatments then progress to stronger ones only
if necessary. As a nutraceutical, Dermylex® represents a safer first
line treatment for the most common forms of Psoriasis.
"We are very pleased to collaborate with Maliderma in their Canadian
retail launch of Dermylex®" stated Mr. Aki Georgacacos, Interim
President and CEO of Botaneco. "Incorporating Dermylex® into
Maliderma's consumer focused product line that includes topical
applications opens further global opportunities for both companies in
"Dermylex® perfectly fits our Maliderma line of efficacious but gentle
products for hair and skin care" stated Mr. John Nikolaou, President of
Maliderma. "We see a bright future for this product which was proven to
be efficacious in several clinical studies. We intend to introduce it
to other well known Canadian retailers and even through our
international network of distribution partners."
Maliderma has developed a dedicated website and promotional campaign to
highlight the benefits of the use of Dermylex®. Please visit www.maliderma.com/supplements.html for more details.
About Botaneco Corp.
Botaneco Corp. specializes in personal care, food and nutraceutical
ingredients. We are committed to developing groundbreaking ingredients
based on our patented technologies, and offering multifunctional,
tangible and documented benefits to formulators and consumers alike.
Botaneco is a global developer and marketer of innovative technologies
that help manufacturers meet the consumers growing demand for natural,
environmentally friendly, personal healthcare products. A competitive
advantage to Botaneco's patented technology over traditional products
in the 'green sector' is the ability to significantly enhance the
performance and versatility of these skin and hair care products. The
Company has also been awarded the Canadian Agri-Food Award of Excellence for its flaxseed technology marketed in the natural food industry.
Botaneco holds patents for its Hydresia® Oleosome, Vegetable Oil Gel,
Dermylex® Whey Protein and Flaxseed Dehulling technology.
About Maliderma Inc
Maliderma specializes in providing cutting edge, best in category,
beauty and hair care products that have the distinct advantage of
incorporating natural actives. All of their designed launch products
provide solutions to problems for which there are little alternatives
free of side effects. Maliderma works with top specialists in their
fields, with the core objective to identify a focused and select group
of products that would resolve common problems and ailments in a
simple, quick, effective way without any side effects.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
SOURCE Botaneco Corp.
For further information:
Chief Financial Officer
Kevin Richardson, PhD